Givinostat: all 25 studies that test it

Page 1 of 1. Open to participants first (4), then studies with results posted, then the rest; newest registration first within each.

• Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Then 6 Years OldRecruitingNCT06769633Phase 2
• Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia VeraRecruitingNCT06093672Phase 3
• Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular DystrophyRecruitingNCT05933057Phase 3
• Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability StudyRecruitingNCT03373968Phase 2/3
• Pharmacokinetics, Safety and Tolerability of ITF2357 in Participants With Chronic Hepatic Impairment and With Normal Hepatic FunctionCompletedNCT06736223Phase 1Results posted
• Givinostat and Metabolites Pharmacokinetics in Urine and Plasma (Part 3)CompletedNCT05860114Phase 1Results posted
• The Potential of Givinostat as DDI Victim in Co-administration P-gp Inhibitor (Part 2)CompletedNCT05845567Phase 1Results posted
• Perpetrator DDI Potential of Givinostat as Inhibitor and Inducer of CYP3A and P-gp ActivityCompletedNCT05492318Phase 1Results posted
• Placebo-Corrected Effects of Therapeutic Dose (100 mg) and Supratherapeutic Dose (300 mg) of ITF2357 (Givinostat) and Moxifloxacin on QT/QTC IntervalCompletedNCT04821063Phase 1Results posted
• Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Becker Muscular DystrophyCompletedNCT03238235Phase 2Results posted
• Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular DystrophyCompletedNCT02851797Phase 3Results posted
• A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia VeraCompletedNCT01901432Phase 1/2Results posted
• A Study to Assess Safety/Tolerability, pk, Effects on Histology, Clinical Parameters of Givinostat in Children With DMDCompletedNCT01761292Phase 1/2Results posted
• Open-Label Extension of the Dose Finding Study (DSC/08/2357/36) in Patients With Poly Juvenile Idiopathic ArthritisTerminatedNCT01557452Not applicableResults posted
• Efficacy and Safety Dose Finding Study of Givinostat to Treat Polyarticular Course Juvenile Idiopathic ArthritisTerminatedNCT01261624Phase 2Results posted
• Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia VeraCompletedNCT00928707Phase 2Results posted
• Effect of ITF2357 on Mucosal Healing in Patients With Moderate-to-severe Active Crohn's DiseaseTerminatedNCT00792740Phase 1/2Results posted
• Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's LymphomaCompletedNCT00792467Phase 1/2Results posted
• Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative DiseasesCompletedNCT00606307Phase 2Results posted
• Open Label, Multicentre Trial to Assess Safety and Efficacy of ITF2357 in Active Systemic Juvenile Idiopathic ArthritisCompletedNCT00570661Phase 2Results posted
• Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative NeoplasmsActive, not recruitingNCT01761968Phase 2
• Phase II Study of Histone-deacetylase Inhibitor ITF2357 in Refractory/Relapsed Lymphocytic LeukemiaTerminatedNCT00792831Phase 2
• Phase II Clinical Trial of ITF2357 In Patients With Relapsed/Refractory Multiple MyelomaTerminatedNCT00792506Phase 2
• phII Study of an HDAC Inhibitor in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma PatientsTerminatedNCT00496431Phase 1/2
• The Efficacy and Safety of ITF2357 in AISStatus unknownNCT00442182Phase 2

← Givinostat overview